Expected surge in the Australian Biotech stocks in 2024 with declining interest rates and increasing M&A

Marc Kennis Marc Kennis, December 15, 2023

 

Australian Biotech stocks could see a massive 2024

Stuart Roberts from Stocks Down Under shares his perspective on the future outlook of Australian biotech stocks.

 

The US takes the lead

According to Stuart, the sector has evolved favourably over his 20 years of coverage, with companies becoming more adept at setting goals and achieving significant progress. This upward trend is illustrated by the success of Neuren (ASX:NEU), which is now valued beyond $2 billion on ASX following drug approval.

Stuart anticipates a prosperous future for the sector, partially spurred by the United States’ cessation of increasing interest rates. Biotech is typically the first industry to respond positively to such a shift, as it attracts marginal risk capital in American markets. On top of this, the sector is experiencing a wave of acquisitions and mergers, with major pharmaceutical companies buying emerging competitors for substantial sums. These factors culminate in creating fertile ground for potential investors.

 

Proteomics International Laboratories

Highlighting one promising company, Stuart refers to Proteomics International Laboratories (ASX:PIQ) and their extensive protein database being used to create valuable diagnostics for kidney disease. The company’s first product is approved and selling in multiple jurisdictions. Stuart reveals that his twenty years of experience places him in a prime position to spot such promising entities amongst the ever-evolving biotech landscape.

 

Our own Stuart Roberts on AusBiz talking Biotechnology

 

 

What are the Best Australian Biotech Stocks to invest in right now?

Check our ASX buy/sell tips

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Nuix

Nuix (ASX:NXL) has quadrupled in 12 months! But is more growth to come?

Nuix (ASX:NXL) has been one of the most controversial companies on the ASX since it listed, but has it turned…

ASX Biotechs

Here are 3 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…

buy the dip

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

‘Buy the dip’ – have you ever heard that term? It implies that when a company’s share price ‘dips’ or decreases,…